Evidence map›Paper›PMID 41680410›Full record

ArticleScientific reports2026

Quantifying improvement of psychotic symptoms in clozapine-treated schizophrenia: clinical note analysis with large language models.

Misa Matsumura, Keiichiro Nishida, Katsunori Toyoda, Kaori Kadoyama, Ryoichi Yano, Tetsufumi Kanazawa, Toshiaki Nakamura, Yosuke Morishima

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Misa MatsumuraEducation and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Keiichiro NishidaDepartment of Neuropsychiatry, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Katsunori ToyodaDepartment of Neuropsychiatry, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Kaori KadoyamaEducation and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Ryoichi YanoEducation and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Tetsufumi KanazawaDepartment of Neuropsychiatry, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Toshiaki NakamuraEducation and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Yosuke MorishimaTranslational research center, University Hospital of Psychiatry and Psychotherapy, University of Bern, Bolligenstrasse 111, Bern, 3000, Switzerland. yosuke.morishima@unibe.ch.

Funding

Japan Society for the Promotion of Science 22K07589Japan Society for the Promotion of Science 25K19067Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung 32003B_192623
6 · The paper itself

Abstract

Symptoms of schizophrenia are often reflected in patients' speech. Natural language processing (NLP) approaches enable quantitative assessment of language-related symptoms in schizophrenia. Previous applications have primarily focused on acute psychopathology or predicting the onset or relapse of psychosis rather than treatment-related improvements. Although electronic health records (EHRs) contain rich longitudinal data, unstructured notes hinder structured quantifications. We applied recent large language models (LLMs) to evaluate symptoms based on speech content recorded in EHRs. We analyzed 5,275 clinical notes from 30 patients with treatment-resistant schizophrenia undergoing clozapine treatment. Three state-of-the-art LLMs rated according to the Brief Psychiatric Rating Scale (BPRS). Complementary analysis included parts-of-speech (POS), bag-of-words (BoW), bigram and Linguistic Inquiry and Word Count (LIWC) analyses. LLM-based BPRS ratings revealed significant decreases in Anxiety, Conceptual Disorganization, Suspiciousness, Unusual Thought Content, Hallucinatory behavior, and Depressive Mood during clozapine treatment. POS analysis indicated an increased use of adjectives per sentence, while LIWC analysis revealed more positive emotional expressions during the later phase of treatment. These findings demonstrate that LLMs can extract clinically meaningful symptom information from unstructured clinical text and capture treatment-related changes in psychosis. This approach premises a low-burden method for supporting clinical judgment using routinely collected EHR data.

Indexed as

Antipsychotic AgentsClozapineLarge Language ModelsNatural Language ProcessingSchizophrenia, Treatment-ResistantAdultAnxietyElectronic Health RecordsFemaleHallucinationsHumansMalePsychiatric Status Rating ScalesAntipsychotic AgentsClozapineBrief psychiatric rating scaleClinical notesLanguage disturbanceLarge language modelNatural language processingPsychosis

Identifiers

PMID41680410
PMCPMC12982610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.